1995
DOI: 10.1002/pd.1970150904
|View full text |Cite
|
Sign up to set email alerts
|

Pregnancy outcome after transcervical cvs with a flexible biopsy forceps: Evaluation of risk factors

Abstract: The pregnancy outcome of 1936 women who had transcervical chorionic villus sampling (CVS) with a flexible biopsy forceps was evaluated. Follow-up until 4 weeks after delivery was 99.4 per cent. Various patient- and procedure-related risk factors for spontaneous loss (fetal or neonatal death) were analysed using stepwise logistic regression analysis. The overall spontaneous loss rate was 4.5 per cent. Factors found to be significantly associated with spontaneous loss were quantity of villi < or = 15 mg (relativ… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

1997
1997
2002
2002

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 10 publications
(4 citation statements)
references
References 24 publications
0
4
0
Order By: Relevance
“…Clinicians can thus take advantage of the developments in recombinant DNA technology, broadening the range of gene defects that can be detected prenatally. Most large reports on CVS either represent collaborative efforts or are from centres in which at least two or more operators of different technical levels have contributed to the clinical experience (Canadian Collaborative CVS-Amniocentesis Clinical Trial Group, 1989;Jahoda et al, 1989;Rhoads et al, 1989;Hallak et al, 1992;Jackson et al, 1992; MRC Working Party on the Evaluation of Chorionic Villus Sampling, 1991;Smidt-Jensen et al, 1992;Williams et al, 1992;Ammala et al, 1993;Jackson and Wapner, 1993;Palo et al, 1994;Lunshof et al, 1995). Details of a large experience by a single operator should further delineate the potential of CVS.…”
Section: Introductionmentioning
confidence: 99%
“…Clinicians can thus take advantage of the developments in recombinant DNA technology, broadening the range of gene defects that can be detected prenatally. Most large reports on CVS either represent collaborative efforts or are from centres in which at least two or more operators of different technical levels have contributed to the clinical experience (Canadian Collaborative CVS-Amniocentesis Clinical Trial Group, 1989;Jahoda et al, 1989;Rhoads et al, 1989;Hallak et al, 1992;Jackson et al, 1992; MRC Working Party on the Evaluation of Chorionic Villus Sampling, 1991;Smidt-Jensen et al, 1992;Williams et al, 1992;Ammala et al, 1993;Jackson and Wapner, 1993;Palo et al, 1994;Lunshof et al, 1995). Details of a large experience by a single operator should further delineate the potential of CVS.…”
Section: Introductionmentioning
confidence: 99%
“…Transcervical CVS was performed, between 10 and 13 weeks of gestation, by a small biopsy forceps (Lunshof et al, 1995). Immediately after the procedure, 20 ml of peripheral blood were drawn and collected in EDTA tubes.…”
Section: Patientsmentioning
confidence: 99%
“…In this study 20 transcervically obtained samples of normal male fetuses were examined. All biopsies were taken by a¯exible biopsy forceps (Lunshof et al, 1995) with a mean biopsy size of 32 mg (range 10±80 mg).…”
Section: Methodsmentioning
confidence: 99%